secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001680367-24-000012
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs reports Q4 net loss $17.7M, cash $130.6M; SL-172154 data expected mid-2024; Ono deal up to $227M
--------------------------------------------------------------------------------

- Net loss $17.7M (Q4 2023) vs $25.4M (Q4 2022); full-year $87.3M vs $101.9M; cash $130.6M at year-end.
- Positive Phase 1A/B SL-172154 data in HR-MDS and TP53m AML; completed initial enrollment for expansion cohorts.
- Completed Phase 1B SL-172154 + PLD trial in PROC with positive interim data; all mid-2024 updates expected.
- Strategic collaboration with Ono Pharma for autoimmune targets; up to $227M in milestones plus tiered royalties.
- Completed $50M public offering in Q4 2023; cash runway extended into 2026 beyond Phase 1 readouts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000168036724000012/0001680367-24-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000168036724000012/sttk-20240229.htm
  HTML page:      https://secwatch.observer/filing/0001680367-24-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer